Compass Therapeutics (CMPX) Current Leases (2021 - 2026)

Compass Therapeutics has reported Current Leases for 6 years, with the latest figure at $1.4 million in Q1 2026.

• Quarterly Current Leases rose 1159.63% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 1159.63% YoY) and the FY2025 annual result came in at $1.0 million, up 195.86% from the prior year.
• Current Leases rose to $1.4 million in Q1 2026 per CMPX's latest filing, from $1.0 million in the prior quarter.
• Over five years, Current Leases peaked at $1.4 million in Q1 2026 and troughed at $109000.0 in Q1 2025.
• A 5-year average of $932352.9 and a median of $1.1 million in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2025 and 2026: Current Leases tumbled 91.09% in 2025, then surged 1159.63% in 2026.
• Over 5 years, Current Leases stood at $1.1 million in 2022, then gained by 9.12% to $1.2 million in 2023, then plunged by 71.76% to $338000.0 in 2024, then jumped by 195.86% to $1.0 million in 2025, then surged by 37.3% to $1.4 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.4 million, $1.0 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.